PMC · DOI:10.1002/alz.70533·July 22, 2025
Reply to “Reconsidering dopaminergic modulation in Alzheimer's disease: A case for levodopa/carbidopa as a disease‐modifying agent”
Zsuzsa Sárkány, Joana Damásio, Sandra Macedo‐Ribeiro, Pedro M. Martins
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Chemicals1
Diseases1
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsParkinson's Disease Mechanisms and Treatments · Alzheimer's disease research and treatments · Genetic Neurodegenerative Diseases